Top 5 Vaccines Manufacturers held 76% of the Global Vaccines Market

12 February 2019
Pharma

Visiongain has launched a new pharma report Vaccines Manufacturers Market Report : Merck & Co., Sanofi, Pfizer, GlaxoSmithKline, Johnson & Johnson, AstraZeneca, Emergent Biosolutions, Other Companies

The world vaccines market is set to grow steadily over the next 10 years. This growth is mainly driven by a global ageing population, as the elderly are more prone to contracting infections due to their pre-existing health conditions and a weak immune system. Demand from the emerging markets further drive growth as their middle class gets wealthier and demand better healthcare systems, furthermore the high birth rates in the emerging markets will feed the paediatric vaccines segment. Moreover, the vaccine industry benefits from strong research and development leading to continuous innovation. Technological advancements will be made in vaccine delivery and administration. As a result, the development of more efficient technology will reduce costs of vaccine production, making the entire manufacturing and supply chain more efficient.

The lead analyst of the report commented "Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development. New target sites, ways of generating an immune response and method of administration are already being investigated and, in some cases, successfully implemented. Further progress is expected to be made in this field as companies look for other ways to gain a competitive edge over their rivals, which could just be another way of administering an existing vaccine. This factor is expected to provide strong growth opportunities to vaccines manufacturers."

Leading companies featured in the report include Astellas Pharma Inc., AstraZeneca, Bavarian, Nordic, CSL Ltd., Emergent Biosolutions, Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline PLC, Inovio Pharmaceuticals and others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes 4D Printing in Healthcare Market Report to 2031

4D printing technology finds an abundant scope of use in the medical industry and has brought in a significant revolution in the healthcare industry.

09 March 2021

Read

Visiongain Publishes 3D Cell Culture Market Report to 2031

Rising incidence and prevalence of cardiovascular diseases, osteoarthritis disorder, and multiple cancer are expected to be major driving factors for the growth of the 3D Cell Culture market during the forecast period.

09 March 2021

Read

Visiongain Publishes 3D Bioprinting Market Report to 2031

In recent years, there are major technological innovations that have taken place in the 3D bioprinting industry for numerous medical applications, including cancer drugs, bone and cartilage development, skin tissue development, and liver modeling.

09 March 2021

Read

Visiongain Publishes Rare Diseases Market Report 2021-2031

As lockdowns were imposed in all the countries, diagnosis rates went down in majority of countries during the year hitting the drug sales for some period. Although lockdown measures have been eased up in most countries by mid-year 2020, this trend is expected to continue beyond 2020, stock up of medicines by patients is likely to propel the drug sales in majority of the developed economies, which account for majority of rare diseases.

02 March 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever